CYTR Key Stats
- CytRx Corporation Offers Hope for Brain Cancer Patients Dec 5
- 5 Stocks Insiders Love Right Now The Street Dec 4
- CytRx Corporation to Present at the Oppenheimer 24th Annual Healthcare Conference on Wednesday, December 11th, 2013 noodls Dec 4
- CytRx (CYTR) Moves Higher Following CEO Presentation at LD MICRO Conference Street Insider Dec 4
- Top Insider Trades: CYTR TROX KTOS MDGN The Street Dec 4
- Large CytRx (CYTR) Holder Bolsters Stake Street Insider Dec 3
- Large CytRx (CYTR) Holder Adds More Street Insider Dec 3
- CytRx (CYTR) Files 6.44M Common Shelf for Shareholders Street Insider Nov 27
- CytRx to Present at the Sixth Annual LD MICRO “Main Event” Conference in Los Angeles on December 3, 2013 noodls Nov 26
- Positive Indicators Ahead for CytRx (CYTR), Aegis Maintains Buy Street Insider Nov 25
CYTR Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). CytRx is up 35.34% over the last year vs S&P 500 Total Return up 30.68%, Lpath down 32.11%, and Ariad Pharmaceuticals down 80.47%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for CYTR
Pro Strategies Featuring CYTR
Did CytRx make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene.